Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4 -hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment | Zendy

Eliford Ngaimisi | Zendy; Omary Minzi | Zendy; Sabina Mugusi | Zendy; Philip Sasi | Zendy; K. Riedel | Zendy; Akira Suda | Zendy; N. Ueda | Zendy; M Bakari | Zendy; Mohammed Janabi | Zendy; Ferdinand Mugusi | Zendy; Leif Bertilsson | Zendy; Jürgen Burhenne | Zendy; Eleni Aklillu | Zendy; Ulf Diczfalusy | Zendy

Open Access

Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4 -hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment

Author(s) -

Eliford Ngaimisi,

Omary Minzi,

Sabina Mugusi,

Philip Sasi,

K. Riedel,

Akira Suda,

N. Ueda,

M Bakari,

Mohammed Janabi,

Ferdinand Mugusi,

Leif Bertilsson,

Jürgen Burhenne,

Eleni Aklillu,

Ulf Diczfalusy

Publication year - 2014

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dku286

Subject(s) - efavirenz , cyp2b6 , rifampicin , cyp3a , pharmacology , pharmacokinetics , reverse transcriptase inhibitor , medicine , gastroenterology , tuberculosis , cyp3a4 , human immunodeficiency virus (hiv) , cytochrome p450 , virology , antiretroviral therapy , viral load , metabolism , pathology

To assess the effect of the major efavirenz metabolizing enzyme (CYP2B6) genotype and the effects of rifampicin co-treatment on induction of CYP3A by efavirenz.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research